News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
217 Results
Type
Article (2)
Company Profile (1)
Press Release (214)
Section
Business (39)
Drug Development (33)
FDA (28)
Job Trends (5)
News (108)
Policy (12)
Tag
Academia (1)
Alliances (13)
Approvals (28)
Best Places to Work (4)
C2C Services and Suppliers (8)
Clinical research (32)
Diabetes (1)
Earnings (7)
Europe (7)
Events (14)
FDA (28)
GLP-1 (1)
Healthcare (21)
Hotbed/Location (186)
Job creations (3)
Legal (3)
Metabolic disorders (1)
New Jersey (3)
New York (1)
NextGen Class of 2024 (1)
Obesity (1)
People (13)
Pharmaceutical (1)
Phase II (5)
Phase III (23)
Postmarket research (5)
Real estate (4)
Regulatory (9)
United States (4)
Date
Last 30 days (1)
Last 365 days (8)
2024 (7)
2023 (5)
2022 (1)
2021 (8)
2020 (11)
2019 (15)
2018 (8)
2017 (15)
2016 (27)
2015 (6)
2014 (16)
2013 (17)
2012 (13)
2011 (12)
2010 (23)
217 Results for "NovoNordiskUS".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Novo Nordisk to present new data from key diabetes and obesity trials at the 60th Annual Meeting of the European Association for the Study of Diabetes
September 6, 2024
·
5 min read
Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes.
June 27, 2024
Press Releases
New pooled analysis published in The Lancet demonstrated reduced risk of combined CV death or worsening heart failure with semaglutide
September 2, 2024
·
10 min read
Drug Development
Ozempic® (semaglutide) injection 1 mg demonstrated reduction in risk of kidney disease-related events in Phase 3 FLOW trial presented at the 84th Scientific Sessions of the American Diabetes Association
Novo Nordisk today presented the full results from FLOW, its phase 3b kidney outcomes trial investigating the effects of once-weekly injectable semaglutide 1 mg in adults with type 2 diabetes and chronic kidney disease (CKD), at the 84th Annual Scientific Sessions of the American Diabetes Association (ADA).
June 24, 2024
·
8 min read
Pharm Country
Novo Nordisk launches national Wegovy® campaign, Power of Wegovy®
Novo Nordisk launched The Power of Wegovy®, a new national campaign. The campaign aims to educate on the clinical data of Wegovy® 2.4 mg injection and reflect the collective empowerment people living with obesity can feel when they don’t have to manage their weight alone.
June 3, 2024
·
9 min read
BioCapital
Empowering Change: AMCP Foundation partners with Moda Health and Novo Nordisk Inc., launching a Health Disparities Research Internship
Intern alumni from Moda Health and Novo Nordisk Inc. join forces with the AMCP Foundation for a groundbreaking Health Disparities research internship, appointing Daria Sinclair, a PharmD Candidate at Howard University, College of Pharmacy, as the inaugural intern.
April 3, 2024
·
4 min read
FDA
Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity
Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Wegovy® to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight along with a reduced calorie diet and increased physical activity.
March 8, 2024
·
14 min read
Pharm Country
Coronavirus (COVID-19) resources available from Novo Nordisk in the US
We recognize that people with chronic diseases, including diabetes, obesity and hemophilia, are at increased risk during this pandemic and Novo Nordisk is taking measures to support the communities we serve throughout the COVID-19 pandemic.
April 2, 2020
·
3 min read
Pharm Country
Novo Nordisk to present new cardiometabolic disease data, including results from SELECT, at the annual American Heart Association Scientific Sessions
Novo Nordisk announced the upcoming presentation of new data that helps reinforce the company’s commitment to driving change and addressing unmet needs of people living with cardiometabolic diseases.
November 7, 2023
·
4 min read
Pharm Country
Novo Nordisk issues voluntary nationwide recall of Levemir®, Tresiba®, Fiasp®, Novolog® and Xultophy® product samples due to improper storage temperature conditions
Novo Nordisk is voluntarily recalling 1,468 product samples listed in the table below of Levemir®, Tresiba®, Fiasp®, Novolog® and Xultophy®, to the consumer level.
May 7, 2021
·
4 min read
1 of 22
Next